<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-93365</identifier>
<setSpec>0210-5691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Toxic epidermal necrolysis treated with cyclosporin A</dc:title>
<dc:description xml:lang="en">Lyell&#146;s syndrome or toxic epidermal necrolysis (TEN) is an extremely rare and dangerous severe skin disorder characterized by a high proportion of cutaneous lesions leading tonecrosis and subsequent shedding of the epidermis over large areas of skin after an idiosyncraticreaction triggered by a drug. The patients who suffer it pathophysiologically have similar complications to those seen in major burns.TEN traditionally has been treated with immunomodulators such as glucocorticoids, intravenousgammaglobulin, cyclophosphamide, thalidomide or plasmapheresis. A variable, and sometimes contradictory response, has been obtained in some series.Cyclosporin A has been tested as a single immunomodulator in patients with TEN since the end of the 90 s in a limited number series. The results have improved in regards to survival compared with studies with other drugs.We report three consecutive cases of toxic epidermal necrolysis treated with cyclosporin Ain this article (AU)</dc:description>
<dc:creator>Ballesteros Martínez, J. L</dc:creator>
<dc:creator>Fernández Carmona, A</dc:creator>
<dc:creator>Garzón Gómez, A</dc:creator>
<dc:creator>Díaz Redondo, A</dc:creator>
<dc:creator>Olivencia Peña, L</dc:creator>
<dc:creator>Carlos Frías Pareja, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome de Lyell o necrólisis epidérmica tóxica (NET) es una toxicodermia extremadamente grave e infrecuente; se caracteriza por la necrosis y el posterior desprendimiento de la epidermis en grandes áreas cutáneas tras una reacción idiosincrásica a un fármaco. Los pacientes que la padecen presentan idénticas complicaciones fisiopatológicas que los grandes quemados. Tradicionalmente se ha tratado con inmunomoduladores como los corticoides, inmunoglobulinas, ciclofosfamida, talidomida o plasmaférisis, obteniéndose una respuesta variable y enalgunos casos contradictoria.Desde finales de los años noventa, se ha ensayado en series limitadas la ciclosporina A comoinmunomodulador único en pacientes con NET, mejorando resultados en términos de supervivencia respecto a estudios con otros fármacos. En este artículo se presentan 3 casos consecutivos de NET tratados con ciclosporina A (AU)</dc:description>
<dc:source>Med. intensiva (Madr., Ed. impr.);35(7): 442-445, oct. 2011. ilus, tab</dc:source>
<dc:identifier>ibc-93365</dc:identifier>
<dc:title xml:lang="es">Tratamiento de necrólisis epidérmica tóxica con ciclosporina A</dc:title>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d30164^s22073</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d22210^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5175^s22027</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29589^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201110</dc:date>
</metadata>
</record>
</ibecs-document>
